How 3 Mass. companies are using AI to design drugs

  • 📰 WBUR
  • ⏱ Reading Time:
  • 38 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Brasil Notícia Notícia

Brasil Últimas Notícias,Brasil Manchetes

Biotechnology and pharmaceutical companies – and their investors – are betting the newest generation of artificial intelligence can help unleash novel treatments for everything from COVID to cancer and chronic diseases.

Protein structures generated by artificial intelligence at Somerville-based Generate: Biomedicines. This story was featured in WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox,One way artificial intelligence promises to revolutionize health care is in the realm of drug development. Creating new treatments for diseases is anthat typically involves lots of failure, sometimes over a decade or longer.

“We've built all those, we've tested all those and we've learned from all of those to refine our computational models,” Nally said. “And what's really exciting is that the answers are just getting better and better.” “These are things that we know have a biological benefit,” Georgiadis said. “I call them hidden in plain sight — keys that can connect to our biology, but we haven't been able to look at and tour this landscape before.”

The real proof will come after clinical trials, which will show whether drugs designed with help from AI tools are as safe and effective as scientists hope. Montai is about a year and a half away from putting some of its first drugs into clinical trials, Georgiadis estimated.

 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 274. in BR

Brasil Últimas Notícias, Brasil Manchetes